Issues in antibiotic therapy for hospital-acquired and ventilator-associated pneumonia: emerging concepts to improve outcomes

References

• Martin-Loeches I. Current concepts in community and ventilator associated lower respiratory tract infections in ICU patients. Antibiotics (Basel). 2020 Jul;5(9):380.
   Google Scholar
• Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122(1):262–268. .
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Micek ST, et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596. .
   PubMed Web of Science ®Google Scholar
• Shorr AF, Combes A, Kollef MH, et al. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med. 2006;34(3):700–706. .
   PubMed Web of Science ®Google Scholar
• Bandić-Pavlović D, Zah-Bogović T, Žižek M, et al. Gram-negative bacteria as causative agents of ventilator-associated pneumonia and their respective resistance mechanisms. J Chemother. 2020;18:1–15.
   Google Scholar
• Luyt CE, Hékimian G, Koulenti D, et al. Microbial cause of ICU-acquired pneumonia: hospital-acquired pneumonia versus ventilator-associated pneumonia. Curr Opin Crit Care. 2018;24(5):332–338. .
   PubMed Web of Science ®Google Scholar
• Corcione S, Lupia T, Maraolo AE, et al. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Curr Opin Infect Dis. 2019;32(6):663–673. .
   PubMed Web of Science ®Google Scholar
• Gupta V, Ye G, Olesky M, et al. Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013-2017. BMC Infect Dis. 32(1): 742. 2019. .
   Google Scholar
• Ayobami O, Willrich N, Suwono B, et al. The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-net data from 2013 to 2017. Antimicrob Resist Infect Control. 2020;9(1):89. .
   PubMed Web of Science ®Google Scholar
• Koulenti D, Tsigou E, Rello J. Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study. Eur J Clin Microbiol Infect Dis. 2017;36(11):1999–2006.
   PubMed Web of Science ®Google Scholar
• Vincent JL, Sakr Y, Singer M, et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA. 2020 Mar:24. DOI:https://doi.org/10.1001/jama.2020.2717
   Google Scholar
• Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012-2017. N Engl J Med. 2020;382(14):1309–1319. .
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia. Chest. 2019;155(6):1119–1130.
   PubMed Web of Science ®Google Scholar
• Zaragoza R, Vidal-Cortés P, Aguilar G, et al. Update of the treatment of nosocomial pneumonia in the ICU. Crit Care. 2020;24(1):383. .
   PubMed Web of Science ®Google Scholar
• Sarda C, Fazal F, Rello J. Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat? Expert Rev Respir Med. 2019;13(8):787–798.
   PubMed Web of Science ®Google Scholar
• Pickens CI, Wunderink RG. Principles and practice of antibiotic stewardship in the ICU. Chest. 2019;156(1):163–171.
   PubMed Web of Science ®Google Scholar
• Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. Clin Pharmacokinet. 2016;55(12):1507–1520.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621–629. .
   PubMed Web of Science ®Google Scholar
• Benítez-Cano A, Luque S, Sorlí L, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care. 24(1): 55. 2020. .
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236–244. .
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016;42(10):1535–1545. .
   PubMed Web of Science ®Google Scholar
• Yu Z, Pang X, Wu X, et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One. 13(7): e0201667. 2018. .
   PubMed Web of Science ®Google Scholar
• Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020;156(1):430.
   Google Scholar
• Chen IH, Nicolau DP. Augmented renal clearance and how to augment antibiotic dosing. Antibiotics (Basel). 2020;42(7):393. .
   Google Scholar
• Baptista JP, Roberts JA, Udy AA. Augmented renal clearance: a real phenomenon with an uncertain cause. Anaesth Crit Care Pain Med. 2019;13(4):335–336.
   Google Scholar
• Nei AM, Kashani KB, Dierkhising R, et al. Predictors of augmented renal clearance in a heterogeneous ICU population as defined by creatinine and cystatin C. Nephron. 2020;144(7):313–320. .
   PubMed Web of Science ®Google Scholar
• Baptista JP, Martins PJ, Marques M, et al. Prevalence and risk factors for augmented renal clearance in a population of critically Ill patients. J Intensive Care Med. 2020;35(10):1044–1052.
   PubMed Web of Science ®Google Scholar
• Carrié C, Chadefaux G, Sauvage N, et al. Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: a before and after study. Crit Care. 23(1): 379. 2019. .
   PubMed Web of Science ®Google Scholar
• Giamarellou H. Epidemiology of infections caused by polymyxin-resistant pathogens. Int J Antimicrob Agents. 2016;144(6):614–621.
   Google Scholar
• Lyu C, Zhang Y, Liu X, et al. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. BMC Infect Dis. 2020;18(1):296.
   Google Scholar
• Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care. 2019;23(1):383. .
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Eur Curr Opin Crit Care. 2018;24(5):347–352.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. .
   PubMed Web of Science ®Google Scholar
• Kollef MH, Ricard JD, Roux D, et al. A randomized trial of the amikacin fosfomycin inhalation system for the adjunctive therapy of gram-negative ventilator-associated pneumonia: IASIS trial. Chest. 2017;151(6):1239–1246. .
   PubMed Web of Science ®Google Scholar
• Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2020;20:330–340.
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. A novel algorithm to analyze epidemiology and outcomes of carbapenem resistance among patients with hospital-acquired and ventilator-associated pneumonia: a retrospective cohort stud. Chest. 2019;155(6):1119–1130. .
   PubMed Web of Science ®Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America antimicrobial treatment guidence: gram-negative bacterial infections. Clin Infect Dis. 2020 Oct 27:ciaa1478. DOI:https://doi.org/10.1093/cid/ciaa1478
   Google Scholar